HRAS is detected as a mutational cancer driver in 2 cancer types: Thyroid carcinoma, Head and neck squamous cell carcinoma and in the PAN-cancer analysis

Ensembl id ENSG00000174775
Mutated samples
Coding Sequence 54 (0.8%)
Protein Affecting 48 (0.7%)
Mode of action Activating
Known driver Yes
Cancer type Signals (Biases)
Clust Clustered Mutations FM Functional Mutations Rec Recurrent Mutations
This plot shows the most recurrently mutated cancer types in all HRAS gene mutations. Each bar of the histogram indicates the amount of samples with PAMs.

Cancer type Driver Mutated samples (CS) Mutated samples (PAM) % Mutated samples (PAM)
Head and neck squamous cell carcinoma Yes 14 14 3.73
Thyroid carcinoma Yes 12 12 3.73
Lung squamous cell carcinoma Yes 5 5 2.87
Cutaneous melanoma Yes 7 5 1.36
Bladder carcinoma Yes 4 4 4.08
Prostate adenocarcinoma Yes 2 2 0.82
Lung adenocarcinoma No 2 2 0.51
Breast carcinoma No 2 1 0.09
Renal clear cell carcinoma No 1 1 0.24
Neuroblastoma No 2 1 0.48
Small cell lung carcinoma No 2 1 1.45
Hepatocarcinoma No 1 0 0.00
The mutations needle plot shows the distribution of the observed cancer mutations along the protein sequence and it's possible mutational clusters and hotspots. The needles' height and head size represent mutational recurrence. Needles of different categories that fall in the same amino acid residues are stacked.

Variant Locus Samples AA pos AA change Consequence